Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France

• Principais autores: Matthieu Lehmann (Autor), Elisangela Arbo (Autor), Jean-Luc Pouly (Autor), Paul Barrière (Autor), Lauren Amy Boland (Autor), Samuel George Bean (Autor), Julian Jenkins (Autor)
• Formato: Livro
• Publicado em: Elsevier, 2024-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Objective: The study assessed cost-effectiveness of follitropin alfa biosimilar versus the originator in terms of cost per cumulative live-birth (CLB) for the French healthcare system based on real-world evidence. Follitropin alfa biosimilars have been shown to have comparable clinical outcomes to t...